Debt-free Balance SheetA zero-debt capital structure materially reduces refinancing risk and interest obligations, giving management flexibility to allocate existing capital toward R&D, commercialization and pilot programs. Over a 2–6 month horizon this improves resilience while the company scales.

Strong Recent Revenue ReboundA ~+90% TTM revenue rebound signals improving commercial traction and demand validation for the product suite. Sustained top-line growth supports scaling of operations and can help spread fixed costs, improving odds of moving toward positive operating leverage.

Proprietary Acoustofluidic PlatformA differentiated, label-free acoustic sorting platform addresses structural growth in cell therapy and bioprocessing. Durable competitive advantage comes from specialized tech fit for continuous-flow manufacturing, increasing likelihood of sustained customer demand as the industry matures.

Bears Say

High Cash BurnPersistent -€16–17M operating/free cash flow indicates material cash burn that will require external financing or strong margin improvement to sustain growth. Over months, burn constrains hiring, commercialization and pilot expansion until cash flow turns positive or funding is secured.

Weak Margins And Large Operating LossesA ~16% gross margin combined with an ~-217% EBIT margin reflects structural profitability challenges. Low gross margins limit the company's ability to self-fund growth and mean achieving sustainable profits will require either substantial margin expansion or much higher recurring revenue levels.

Negative Returns And Dilution RiskDeeply negative ROE (~-93%) and ongoing losses erode equity and raise the probability of additional capital raises. Over a 2–6 month horizon, this increases shareholder dilution risk and may shift management focus from execution to securing funding.

ACOU FAQ

What was AcouSort AB’s price range in the past 12 months?

AcouSort AB lowest stock price was kr2.03 and its highest was kr8.90 in the past 12 months.

What is AcouSort AB’s market cap?

AcouSort AB’s market cap is kr55.45M.

When is AcouSort AB’s upcoming earnings report date?

AcouSort AB’s upcoming earnings report date is Feb 25, 2026 which is in 9 days.

How were AcouSort AB’s earnings last quarter?

AcouSort AB released its earnings results on Nov 26, 2025. The company reported -kr0.127 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.127.

Is AcouSort AB overvalued?

According to Wall Street analysts AcouSort AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AcouSort AB pay dividends?

AcouSort AB does not currently pay dividends.

What is AcouSort AB’s EPS estimate?

AcouSort AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AcouSort AB have?

AcouSort AB has 21,163,902 shares outstanding.

What happened to AcouSort AB’s price movement after its last earnings report?

AcouSort AB reported an EPS of -kr0.127 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.

Which hedge fund is a major shareholder of AcouSort AB?

Currently, no hedge funds are holding shares in SE:ACOU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AcouSort AB

AcouSort AB (publ), a technology company, develops products and solutions for automated preparation of biological samples based on acoustofluidics technology for researchers and life science companies. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, an integrated blood plasma separation module that enables in-line analysis of blood plasma from whole blood samples; and AcouWash, a benchtop research instrument for label-free separation of target cells from various samples. The company was founded in 2010 and is based in Lund, Sweden.